Skip to main content

Tina Wu, MD, MBA

Tina Wu, MD, MBA, is the Senior Director of Clinical Product Strategy at Ro. Double board-certified in Emergency Medicine and Obesity Medicine, she’s also an associate professor and current attending physician in the Emergency Department of the Greater Los Angeles VA Healthcare System and Northwell Health. 

Prior to joining Ro, Dr. Wu was the medical lead at Cloud Health Medical Systems and Sunrise Health and, earlier, the chief medical officer at Waltz Health. Before holding positions at the aforementioned start-ups, she worked at NYU Langone Health in New York: first as the associate chief of service at the Ronald O. Perelman Department of Emergency Medicine and then as the medical director of Kimmel Pavilion 11. During her tenure at NYU Langone Health, Dr. Wu also ran a COVID-19 acute care unit—a role she took on at the height of the pandemic. 

Dr. Wu received BA/BS degrees in Molecular and Cellular Biology and Psychology from the University of Arizona. She then went on to get  an MBA from Harvard Business School and an MD from UCLA David Geffen School of Medicine. Upon graduating medical school, Dr. Wu pursued her residency in Emergency Medicine at NYU Langone Health/Bellevue Hospital Center. Working in urgent care afforded Dr. Wu the opportunity to treat individuals from diverse backgrounds, many of whom were vulnerable and underrepresented. Her commitment to serving these populations ultimately—and somewhat naturally—extended into Obesity Medicine, where she saw a similar need to combat stigma surrounding certain diseases and provide compassionate, patient-centered care. Dr. Wu has also completed a Global Health Fellowship with the American Medical Student Association (AMSA) in Washington, D.C.  and a National Security Education Fellowship in Beijing, China.

In addition to publishing many peer-reviewed chapters and papers, Dr. Wu has also received several awards, including being named one of Time Magazine's “200 Brightest, Most Industrious Minds in America” among students and teachers. She’s also been inducted into the prestigious Galileo Circle at the University of Arizona and named rookie “Attending of the Year” at NYU Langone Health/Bellevue Hospital Center.

After spending 13 years in New York, Dr. Wu now calls Los Angeles home. She spends her free time with her husband putting in 10,000 steps daily and playing board games and puzzles with her sons, Dean and Jude. You can find Dr. Wu on Linkedin.  

Education 

Certifications

Professional accomplishments 

  • Founding member, Pine Health 

  • Founding member, Waltz Health

  • “200 Brightest, Most Industrious Minds in America,” Time Magazine (1998)

  • Winner, “Rising Star” Award, Harvard Business School Women’s Association of Greater New York (2020)  

  • Winner, “Attending of the Year” Award, NYU Langone Health/Bellevue Hospital Center (2015)

  • Course Director and Lecturer, National American Academy of Emergency Physicians — Emergency Department Directors Academy 

  • Over 100 national presentations, posters, and peer-reviewed publications 

Published articles 

  • Larkin, I., Ang, D., Steinhart, J., Chao, M., Patterson, M., Sah, S., Wu, T., Schoenbaum, M., Hutchins, D., Brennan, T., & Loewenstein, G. (2017). Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing. JAMA, 317(17), 1785–1795. doi:10.1001/jama.2017.4039

  • Liao, C. L., Lee, M. Y., Tyan, Y. S., Kok, L. F., Wu, T. S., Koo, C. L., Wang, P. H., Chao, K. C., & Han, C. P. (2009). Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Journal of translational medicine, 7, 37. doi:10.1186/1479-5876-7-37

  • Han, C. P., Lee, M. Y., Kok, L. F., Ruan, A., Wu, T. S., Cheng, Y. W., Tyan, Y. S., & Lin, C. Y. (2009). Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 28(5), 489–496. doi:10.1097/PGP.0b013e31819e8ab4